NutrigeneAI Biotech Limited (NBL) is a pioneering biotechnology company founded in Hong Kong in December 2023 by Prof. Jack Wong (CUHK) and Mr. Gary Ng (CFO), led by Dr. Bill Wong (CEO). NutrigeneAI is dedicated to transforming the treatment landscape for vascular diseases by developing first-in-class regenerative cell therapies. We are pioneering a patented Type 2 cytokine-primed iPSC-derived Endothelial Cell (iPSC-EC) platform. Our mission is to provide transformative limb-salvage and tissue regeneration solutions for patients suffering from Peripheral Arterial Disease (PAD), Critical Limb Ischemia (CLI), and Acute Ischemic Stroke. “To build a world with no patient has been left behind without an choice!”

NutrigeneAI Biotech Limited (Maiyuan Chuangke (Shenzhen) Biotechnology Co., Ltd.) is a biotechnology company founded in Hong Kong. Its core technology is derived from the cutting-edge research of Professor Wong Wing-tak from the School of Life Sciences at The Chinese University of Hong Kong (CUHK), who has dedicated years to studying induced pluripotent stem cell (iPSC) and cardiovascular fields. The company focuses on developing allogeneic endothelial cell (EC) therapies for the treatment of peripheral arterial disease (PAD), critical limb ischemia (CLI), diabetic foot (DBF) using iPSC-derived endothelial cells (iPSC-EC).

**NutrigeneAI’s Lead Pipeline: NBL-EC01-P**

*   **Primary Indications**: Peripheral arterial disease (PAD), critical limb ischemia (CLI), Buerger’s disease (a rare disease), and diabetic foot (DBF).
    
*   **Potential Expanded Indications**: Atherosclerosis, erectile dysfunction (ED), and stroke.
    

These areas present significant unmet clinical needs, limited treatment options, and a market potential exceeding **RMB 150 billion**.

**Current Financing Progress**The company is currently conducting a Pre-A round financing of approximately **HKD 20 million**, with **HKD 10 million** already completed.

**Clinical Development & Collaborations**

1.  **Shanghai General Hospital**The team has reached a collaboration with Shanghai General Hospital to prepare for
    
    IIT (Investigator-Initiated Trial) clinical details. It is expected to enroll **5–20 CLI patients** for IIT by **2027**.
    
2.  **West China Hospital of Sichuan University (Hainan Boao Lecheng Branch)**We have signed a letter of intent for collaboration with West China Hospital of Sichuan University (Hainan Boao Lecheng Branch) to introduce the iPSC regenerative therapy technology developed by Professor Wong Wing-tak’s team at CUHK. This collaboration will align with the clinical needs of multiple departments for ischemic diseases, refine IIT application details, and leverage the advantages of China’s pilot zones for conducting and applying for drug IIT clinical research. The first IIT patient is expected to be enrolled by the end of **2026**.
    

**Long-Term Goals**Our goal is to obtain **medical technology approval (in Hainan)** and an **IND (

My Sourcing

NutrigeneAI Biotech Limited

Company Information

Contact